A few years earlier, a proteomic study by LC-MS/MS revealed some aspects of the molecular mechanism of IBD response to Infliximab, an anti-TNF agent commonly used to control inflammation in IBD patients. The gene discussed is TNF; the disease is inflammatory bowel disease.